Clinical Medicine Insights-Endocrinology and Diabetes, published by SAGE Publications Ltd, is a dynamic open-access journal dedicated to advancing the field of endocrinology and diabetes through high-quality research. Since its inception in 2008, this journal has become an essential resource for researchers, healthcare professionals, and students interested in the latest innovations and clinical practices in the realm of diabetes management and endocrine disorders. With an impressive 2023 JCR Q2 ranking in both Endocrinology, Diabetes and Metabolism and Internal Medicine, the journal serves as a pivotal platform for scholarly discussions, focusing on the convergence of clinical insights and therapeutic advancements. By offering an open-access model, the journal ensures that its articles are accessible to a global audience, thus promoting the dissemination of knowledge and best practices in the treatment of these critical health issues. The journal's commitment to excellence is reflected in its Scopus rankings, which position it among the noteworthy publications in the field. As it converges from 2009 to 2024, Clinical Medicine Insights-Endocrinology and Diabetes remains a cornerstone for impactful research, inspiring collaborations and serving as a vital reference for ongoing developments in patient care and treatment methodologies.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

Nature Reviews Endocrinology is a premier journal published by NATURE PORTFOLIO, providing comprehensive and critical reviews in the rapidly evolving field of endocrinology. Established to foster advanced understanding, it has become a vital resource for researchers, professionals, and students alike. With an impressive impact factor and a prominent ranking of Q1 in both Endocrinology and Endocrinology, Diabetes, and Metabolism categories for 2023, the journal is recognized for its high-quality research dissemination, evidenced by its rankings of #2 out of 244 in Medicine and #2 out of 128 in Biochemistry, Genetics, and Molecular Biology. Spanning the years from 2009 to 2024, it focuses on publishing cutting-edge information that shapes current scientific knowledge and clinical practices. The journal offers open access options, ensuring greater visibility and reach for its articles. Located in Germany, this journal remains at the forefront of endocrinology research, significantly contributing to the understanding of hormonal functions and their implications on health. Discover the latest advancements and insights by exploring Nature Reviews Endocrinology.

Diabetologie und Stoffwechsel is a prominent academic journal specializing in the fields of endocrinology, diabetes, and metabolism, published by GEORG THIEME VERLAG KG. Since its inception in 2006, this German journal has strived to disseminate cutting-edge research and innovative findings that advance the understanding of metabolic disorders and the management of diabetes. With an ISSN of 1861-9002 and an E-ISSN of 1861-9010, it caters to a diverse audience ranging from researchers to healthcare professionals and students in the medical field. While it currently holds a Q4 ranking in the 2023 Scopus quartiles for its area, the journal serves as a critical platform for emerging insights and discussions impacting diabetes care and research, fostering collaboration and knowledge-sharing in a rapidly evolving landscape. The convergence of its coverage until 2024 signifies a commitment to ongoing exploration into the complexities of metabolic health, making it a valuable resource for anyone passionate about these vital areas of health.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

The International Journal of Endocrinology is a premier peer-reviewed journal, published by HINDAWI LTD, focusing on the rapidly evolving fields of endocrinology, diabetes, and metabolism. Since its establishment in 2009, the journal has embraced an Open Access model, ensuring that cutting-edge research is accessible to a global audience without barriers. With an impressive Scopus rank placing it within the top quartiles of related fields, it ranks #103 in Endocrinology, Diabetes and Metabolism, showcasing its significant contribution to the ongoing discourse in these areas. The journal's scope includes original research, reviews, and clinical studies that advance understanding and treatment strategies for endocrine disorders. By bridging the gap between research, clinical practice, and patient care, the International Journal of Endocrinology serves as an essential resource for researchers, practitioners, and students dedicated to the field of endocrinology. Addressed from its headquarters in the United States, this journal not only contributes to academic advancement but also fosters international collaboration in addressing key challenges in endocrinology.

Journal of Endocrinology Metabolism and Diabetes of South Africa, published by Routledge Journals, Taylor & Francis Ltd, serves as a vital platform for advancing research and knowledge dissemination in the fields of endocrinology, metabolism, and diabetes. Since its transition to Open Access in 2012, it has enabled greater accessibility to crucial findings and data, broadening its reach to researchers, practitioners, and students alike. Though its coverage in Scopus was discontinued in 2018, the journal continues to play an important role in fostering discourse in the medical community, as evidenced by its ranking within the 19th and 16th percentiles for Internal Medicine and Endocrinology, diabetes and metabolism, respectively. With its commitment to addressing pressing health issues in South Africa and beyond, this journal remains an invaluable resource for those seeking to understand and tackle the complexities of metabolic diseases.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

Diabetes & Metabolic Syndrome-Clinical Research & Reviews is a leading peer-reviewed journal published by ELSEVIER SCI LTD in the field of endocrinology, diabetes, and internal medicine. With an impressive impact factor evidenced by its high rankings, this journal is positioned in the top quartile (Q1) across multiple categories, including Endocrinology, Diabetes and Metabolism, and Internal Medicine. Spanning from 2007 to 2024, it serves as a vital resource for researchers, healthcare professionals, and students alike, offering comprehensive reviews and innovative clinical research related to metabolic disorders. Located in the Netherlands, the journal emphasizes an open-access approach, ensuring valuable insights are available to a global audience. By publishing high-quality and impactful articles, Diabetes & Metabolic Syndrome not only contributes to the advancement of scientific knowledge but also plays a crucial role in shaping clinical practices and enhancing patient care in the realm of diabetes and metabolic syndrome.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.